alovudine has been researched along with Minimal Disease, Residual in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Cui, Y; Fu, Z; Li, M; Wang, Z; Yu, J; Zhao, F | 1 |
| Cabrera, AR; Chen, L; Han, A; Han, D; Li, Y; Ma, L; Ma, Y; Mu, D; Sun, X; Teng, X; Yu, J; Yue, J; Zhao, S; Zhao, X; Zheng, F; Zheng, J | 1 |
| Aide, N; Bor, C; Joly, F; Paciencia, M | 1 |
| Chao, KS | 1 |
| Hicks, RJ | 1 |
| Egerer, G; Eisenhut, M; Gronkowski, M; Haberkorn, U; Haufe, S; Ho, AD; Kasper, B; Lehnert, T; Mechtersheimer, G | 1 |
1 trial(s) available for alovudine and Minimal Disease, Residual
| Article | Year |
|---|---|
Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
Topics: Aged; Aged, 80 and over; Bone Marrow Cells; Carcinoma, Squamous Cell; Cell Proliferation; Diagnosis, Differential; Dideoxynucleosides; Esophageal Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Inflammation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Positron-Emission Tomography; Tomography, X-Ray Computed | 2010 |
5 other study(ies) available for alovudine and Minimal Disease, Residual
| Article | Year |
|---|---|
(18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI.
Topics: Adult; Aged; Brain Neoplasms; Dideoxynucleosides; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoplasm, Residual; Positron-Emission Tomography; Postoperative Period; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Postchemotherapy residual masses in nonseminomatous germ cell tumor patients: 18F-FLT PET is unlikely to identify mature teratoma, but imaging of alphav beta3 integrin expression could.
Topics: Dideoxynucleosides; Gene Expression Regulation, Neoplastic; Humans; Integrin alphaVbeta3; Neoplasm, Residual; Neoplasms, Germ Cell and Embryonal; Positron-Emission Tomography; Teratoma; Testicular Neoplasms | 2011 |
3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Esophageal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Forecasting; Humans; Mice; Neoadjuvant Therapy; Neoplasm, Residual; Positron-Emission Tomography; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome | 2007 |
The SUV and FLT PET: a tasty alphabet soup or a dog's breakfast?
Topics: Combined Modality Therapy; Data Interpretation, Statistical; Dideoxynucleosides; Disease-Free Survival; Humans; Lymphoma; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity | 2007 |
Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET.
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Dideoxynucleosides; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lymphoma; Male; Middle Aged; Neoplasm, Residual; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals | 2007 |